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Introduction
The initiators of the extrinsic cell death pathway are a subclass 
of TNF superfamily (TNFSF) receptors called death receptors 
(DRs). A common feature of DR signaling is the formation of 
a primary plasma membrane–associated death-inducing signal-
ing complex (DISC) and a secondary independent signaling 
platform in the cytoplasm (complex II). Complex II was first 
demonstrated for TNF-R1 (Micheau and Tschopp, 2003) but 
subsequently was also shown for other DR pathways (Varfolomeev 
et al., 2005; Lavrik et al., 2008). However, the mechanisms 
leading to the formation of these secondary complexes and 
their significance to signaling outcome are still unknown. DR 
signaling pathways are controlled by inhibitors such as cellular 
FLICE-inhibitory protein (FLIP [cFLIP]) or X-linked inhibitor 
of apoptosis (IAP [XIAP]; for review see Meier and Vousden, 
2007). The cFLIP gene can give rise to 11 distinct isoforms, but 
in most cells, a long (cFLIPL) and a short isoform (cFLIPS) are 
the only ones readily detected (for reviews see Kataoka, 2005; 
Budd et al., 2006). cFLIPL has a caspase-like domain lacking the 
critical catalytic residues present in caspase-8 in addition to 
two death effector domains, whereas cFLIPS contains only two 
death effector domains and is structurally related to viral FLIP 
(vFLIP; Thurau et al., 2006). cFLIP isoforms interact with FADD 
(Fas-associated protein with death domain [DD]) and caspase-8, 
are recruited to the DISC, and interfere with caspase activation 
within this signaling platform (Lavrik et al., 2005; Falschlehner 
et al., 2007).
DRs can also cause nonapoptotic, caspase-independent cell 
death and elicit nonapoptotic responses (for reviews see Wajant 
et al., 2003; Kroemer et al., 2009). The significance of these caspase-
independent DR pathways is debated, and there is a need to pro-
vide additional examples in more physiological scenarios. RIP1 
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A role for cellular inhibitors of apoptosis (IAPs [cIAPs]) in preventing CD95 death has been suspected but not previously explained mechanistically. In this 
study, we find that the loss of cIAPs leads to a dramatic 
sensitization to CD95 ligand (CD95L) killing. Surprisingly, 
this form of cell death can only be blocked by a combina-
tion of RIP1 (receptor-interacting protein 1) kinase and cas-
pase inhibitors. Consistently, we detect a large increase in 
RIP1 levels in the CD95 death-inducing signaling complex 
(DISC) and in a secondary cytoplasmic complex (complex II) 
in the presence of IAP antagonists and loss of RIP1- 
protected cells from CD95L/IAP antagonist–induced death. 
Cells resistant to CD95L/IAP antagonist treatment could 
be sensitized by short hairpin RNA–mediated knockdown 
of cellular FLICE-inhibitory protein (cFLIP). However, only 
cFLIPL and not cFLIPS interfered with RIP1 recruitment to the 
DISC and complex II and protected cells from death. These 
results demonstrate a fundamental role for RIP1 in CD95 
signaling and provide support for a physiological role of 
caspase-independent death receptor–mediated cell death.
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MET1 cells but not A5RT3 were sensitized to TRAIL- or CD95 
ligand (CD95L)–mediated cell death in a TNF-independent man-
ner in both short-term (Fig. 1 A) and clonogenic assays (Fig. 1 B). 
DL-induced cell death correlated with phosphatidylserine exter-
nalization (Fig. 1 C and Fig. S4 A) and hypodiploidy (Fig. 1 D). 
Consistent with an apoptotic cell death, we observed processing 
of caspases and PARP (poly[ADP-ribose] polymerase) cleavage 
within 4 h of stimulation with DLs in the presence of the IAP 
antagonist (Fig. 1 E and not depicted). To determine whether IAP 
antagonist–induced loss of cIAPs was important for this increased 
sensitization, we tested SV40 large T immortalized mouse em-
bryonic fibroblasts (MEFs) lacking XIAP, cIAP1, cIAP2, or both 
cIAP1 and -2 (double knockout [DKO]) for their sensitivity to 
CD95L and TRAIL. DKO MEFs demonstrated an increased sen-
sitivity to DLs, and the IAP antagonist slightly decreased the 
viability of these cells, suggesting that sensitivity was largely 
regulated by both cIAP1 and -2 in MEFs (Fig. 2 A). Consistent 
with this hypothesis, loss of XIAP did not sensitize MEFs to DLs 
(Fig. 2 A). Inducible reconstitution of cIAP1 or -2 into DKO 
MEFs (Fig. 2 B) increased the CD95L resistance of the DKOs 
that was lost when cells were cotreated with the IAP antagonist 
(Fig. 2 A, right). In contrast, increased expression of XIAP into 
DKO MEFs did not substantially alter sensitivity of these MEFs 
to the combination of CD95L and IAP antagonist (Fig. 2 C).
Similarly, knockdown of cIAP1 or both cIAPs sensitized 
HaCaT cells to CD95L-induced death despite the fact that there 
was a compensatory rise in the levels of cIAP2 (Fig. 2 D). This 
rise in cIAP2 levels might be explained by posttranslational 
regulation of cIAPs (Conze et al., 2005) or by increased NF-B 
induced by loss of cIAP1 (Vince, J., personal communication). Spe-
cific knockdown of cIAP2 provides further evidence that it plays 
a less important role than cIAP1 in these cells as reported previ-
ously (Diessenbacher et al., 2008), although the knockdown of 
cIAP2 was weaker when compared with cIAP1 knockdown. We 
also inducibly expressed cIAP1 or -2 in HaCaT. Overexpression 
of cIAP2 conferred protection from CD95L-induced cell death in 
the presence of the IAP antagonist (Fig. 2 E). In contrast, induc-
ible overexpression of cIAP1 did not alter sensitivity to CD95L 
nor was it able to protect against the IAP antagonist–mediated 
sensitization to CD95L death, presumably because of the effi-
cient degradation of endogenous and overexpressed cIAP1 
(Fig. S4, C and D). These data argue that endogenous levels of 
cIAPs in HaCaT are sufficient to confer resistance to CD95L-
induced cell death but that loss of both cIAPs sensitizes to CD95-
induced cell death. Our results demonstrate that cIAPs play an 
important role in limiting DL toxicity in both human and mouse 
cell lines.
IAP antagonist/DR-mediated cell death is 
neither entirely caspase dependent nor 
independent and requires RIP1K activity
DR-mediated apoptosis is initiated by DISC-activated caspase-8 
(Peter and Krammer, 2003; Walczak and Haas, 2008). To in-
vestigate whether caspases caused DR-mediated cell death in 
the presence of the IAP antagonist, we used the caspase inhibi-
tor zVAD-fmk. zVAD-fmk blocked cell death when cells were 
stimulated with DLs for 24 h. However, DL-mediated cell death 
(receptor-interacting protein 1) belongs to the RIP kinase family 
but is the only family member with a C-terminal DD (Stanger 
et al., 1995; for review see Festjens et al., 2007). RIP1 knockout 
mice are born but die rapidly because of an increased sensitivity 
to TNF (Kelliher et al., 1998). RIP1, and specifically its DD, was 
reported to be critical for CD95-mediated necrosis independent 
of NF-B–inducing activity or RIP1 kinase (RIP1K) activity 
(Holler et al., 2000; Degterev et al., 2005). The development of 
specific RIP1K inhibitors has facilitated experiments examining 
the functional role of RIP1K in necrosis (Degterev et al., 2008), 
but the precise role or potential targets of the kinase activity of 
RIP1 are unknown (Hitomi et al., 2008).
A major goal of tumor therapies such as DR agonists is 
to overcome transformation-induced apoptosis resistance 
(Hanahan and Weinberg, 2000; Ashkenazi, 2008). However, un-
fortunately, resistant tumor cells are frequently selected during 
treatment, exemplifying the need for novel treatments that can 
further sensitize tumors to DR-mediated apoptosis. IAP antagonists 
are synthetic compounds that were modeled on the N-terminal 
IAP-binding motif of the mitochondrial protein Smac/DIABLO 
(Wright and Duckett, 2005). The XIAP-interfering function of 
Smac-mimetic compounds (IAP antagonists) is crucial for ther-
apeutic efficiency of TNF-related apoptosis-inducing ligand 
(TRAIL) in xenograft tumor models (Vogler et al., 2008). 
Recently, it has become apparent that compounds principally 
designed to target XIAP also target cIAPs by rapid autoubiqui-
tylation and proteasomal degradation of cIAP1 and -2 (Gaither 
et al., 2007; Petersen et al., 2007; Varfolomeev et al., 2007; Vince 
et al., 2007; Bertrand et al., 2008).
Previous studies have shown that cIAPs can inhibit CD95- 
and TRAIL-R–induced apoptosis (McEleny et al., 2004; Wang 
et al., 2005). It is unlikely that their role will be as direct caspase 
inhibitors because cIAPs are rather poor inhibitors of caspase 
activity (Eckelman and Salvesen, 2006). Because cIAPs regulate 
RIP1 in TNF-R1 and RIP1 plays a role in CD95 signaling, we 
have investigated the mechanism of DR cell death in the context 
of IAP inhibition. We show that cIAPs block DR-mediated cell 
death and that in their absence, cell death proceeds in a caspase- 
and RIP1K-dependent manner. Loss of cIAPs results in in-
creased RIP1 recruitment to the DISC and in increased formation 
of complex II, which contains FADD, caspase-8, RIP1, and 
cFLIP isoforms. Surprisingly, different cFLIP isoforms have 
distinct signaling capabilities whenever cIAPs are repressed. 
This function of cIAPs might be used as a target to overcome 
apoptosis resistance in tumor therapy and might also be relevant 
during virus infection or tumor immunity, in which the mode of 
cell death is important (Lotze et al., 2007).
Results
The IAP antagonist sensitizes to death 
ligand (DL)–mediated cell death
We characterized the sensitivity of different keratinocyte cell 
lines and squamous cell carcinoma (SCC) cells with a recently 
described IAP antagonist, compound A (Vince et al., 2007). A 
rapid degradation of cIAP1 and, to a lesser extent, cIAP2 was 
detected after IAP antagonist treatment (Fig. S1 A). HaCaT and 
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typical apoptotic cells demonstrating membrane blebbing, DNA 
condensation, and fragmentation were detectable after CD95L 
treatment and zVAD-fmk fully protected cell death and mem-
brane integrity (Fig. 3 B, left). Caspase inhibition only partly 
protected from cell death in CD95L + IAP antagonist–treated 
cells (Fig. 3 B, right). Dying cells under those conditions showed 
in the presence of the IAP antagonist was only partially blocked 
by zVAD-fmk (Fig. 3 A). One potential explanation for these 
data is that DL treatment in the presence of the IAP antagonist 
induced a caspase-independent form of cell death. To character-
ize the morphology of cell death in these cells, we performed 
fluorescence microscopy experiments. Increased numbers of 
Figure 1. The IAP antagonist sensitizes SCC and HaCaT to DL-mediated apoptosis independent of autocrine TNF secretion. (A) HaCaT, MET1, or A5RT3 
cells were either pretreated with 100 nM of the IAP antagonist (Ant) alone or in combination with 10 µg/ml TNF-R2-Fc for 30 min and then stimulated with 
TRAIL or CD95L. The viability of cells was analyzed by crystal violet assay after 18–24 h as indicated in Materials and methods. Mean and SEM of four 
independent experiments are shown. (B) For clonogenic assays, HaCaT cells were prestimulated with 100 nM of the IAP antagonist for 30 min followed 
by co-stimulation with 2.5 U/ml CD95L for 24 h. Colony formation was assayed as indicated in Materials and methods. One representative experiment 
of a total of three independent experiments is shown. (C–E) HaCaT cells were either prestimulated with 100 nM of the IAP antagonist for 30 min alone 
or stimulated/co-stimulated with 10 U/ml CD95L. (C) Cells were stained with annexin V–Cy5 and PI after 4 h and analyzed by FACS. (D) Cells were 
incubated for 8 h and subsequently analyzed for hypodiploidy by FACS analysis (see Materials and methods). (E) Cells were treated with 100 nM of the 
IAP antagonist, 2.5 U/ml CD95L, or the combination of both in the presence or absence of 10 µg/ml TNF-R2-Fc for the indicated time points. Western blot 
analysis was performed for the expression of cIAP1 and -2, caspase-8 and -3, PARP-1, FADD, and RIP1. -Tubulin served as an internal loading control. 
One of two representative experiments is shown. The asterisk marks an unspecific band. MM, molecular mass.
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Figure 2. cIAPs specifically block CD95L-induced cell death of MEFs and human SCCs. (A) Transformed single knockout or DKO MEFs and respective 
control wild-type (WT) MEFs were treated with 10 ng/ml CD95L or 500 ng/ml TRAIL for 24 h in the presence or absence of 500 nM of the IAP antagonist 
(left). Cells were stained with PI and analyzed by flow cytometry. Four independent cIAP1 and -2 DKO MEFs were infected with inducible mouse cIAP1 or 
Flag-cIAP2 and induced with 10 nM 4-HT for 24 h. Cells were then treated with CD95L and TRAIL for 24 h in the presence or absence of the IAP antagonist, 
 o
n
 August 15, 2010
jcb.rupress.org
D
ow
nloaded from
 
Published December 28, 2009
1041cIAPs inhibit death receptor–mediated death • Geserick et al.
IAPs inhibit recruitment of RIP1 to the 
DISC and suppress the formation of 
complex II
To characterize how cIAPs negatively regulated CD95-mediated 
cell death, we examined the DISC and the receptor-independent 
complex II (Lavrik et al., 2008) in a cell line responsive to the IAP 
antagonist (MET1) and compared it with cells resistant to the IAP 
antagonist (A5RT3). We were readily able to detect recruitment of 
cFLIP, caspase-8, and FADD after CD95L stimulation (Fig. 5 A, 
left). Stimulation of CD95 led to SDS- and -mercaptoethanol– 
insoluble CD95 complexes of higher molecular mass (Feig et al., 
2007), as seen in the CD95 Western blots of our DISC precipitates 
(compare Fig. 5 with Fig. 7). We also detected small amounts of 
RIP1 in the CD95 DISC in both cell types (Fig. 5 A, lanes 3 and 7). 
Given the differential sensitivity, recruitment of FADD, FLIP, 
and caspase-8 to the DISC was remarkably similar in MET1 and 
A5RT3s, either in the presence or absence of the IAP antagonist. 
In contrast, RIP1 recruitment was dramatically increased in the 
CD95 DISC of MET1 in the absence of cIAPs (Fig. 5 A, lanes 3 
and 4), whereas RIP1 recruitment was weaker in A5RT3 cells, 
although still increased by the IAP antagonist (Fig. 5 A, lanes 
7 and 8). When we examined complex II, we observed a simi-
lar stimulation-dependent interaction of FADD, cFLIP, and RIP1 
with caspase-8. These experiments were performed in the pres-
ence of zVAD-fmk during stimulation because caspase inhibitors 
stabilize complex II (Wang et al., 2008). As in the CD95 DISC, 
there was a substantial increase in RIP1 recruitment to complex II 
in the absence of cIAPs compared with CD95L-treated cells alone 
(Fig. 5 A, lanes 19 and 20 and 23 and 24). Our data suggested that 
loss of cIAPs increased the DISC recruitment of RIP1 or repressed 
RIP1 degradation, which translated to an increased level of RIP1 
in complex II.
zVAD-fmk stabilizes both the DISC and complex II 
and allows for the easier detection of DISC and complex II 
components (Micheau et al., 2002; Wang et al., 2008). Thus, 
we tested whether zVAD-fmk affected DISC and complex 
II composition. Reassuringly, the qualitative recruitment of 
RIP1 was almost identical whether cells were treated with 
zVAD-fmk or not, except that RIP1 was cleaved in the ab-
sence of caspase inhibitor as previously published (Fig. 5 B; 
Kim et al., 2000; Martinon et al., 2000). Importantly, this ex-
periment showed that both DISC recruitment and complex II 
formation increase over 1 h and then remain at steady levels 
for the next hour, finally decreasing in abundance within 4 h. 
It also demonstrated the effect of zVAD-fmk in increasing 
the stability of both CD95 DISC and complex II, confirming 
previous studies (Micheau et al., 2002; Wang et al., 2008). 
a rounded shape, a lack of DNA condensation, and a later 
disruption of cell membranes, which are indicative of caspase-
independent cell death (Fig. 3 B). These data suggested that cIAPs 
inhibit a cryptic caspase-independent death pathway that ema-
nates from DRs. CD95 has the potential to activate a caspase- 
independent form of cell death via RIP1 (for review see Festjens 
et al., 2007). Because cIAPs are essential to ubiquitylate RIP1 
in the TNF-R1 pathway (Bertrand et al., 2008), we hypothesized 
that RIP1 was required for this form of cell death. Therefore, we 
generated cell lines with decreased levels of RIP1 using stable 
short hairpin RNA (shRNA) expression (Fig. 3 C) and tested for 
sensitivity to CD95L/IAP antagonist–induced death. Interest-
ingly RIP1 knockdown cells were remarkably resistant to sen-
sitization to DL-mediated cell death by the IAP antagonist in 
short-term viability (Fig. 3 D) or clonogenic assays (Fig. 3 E).
To rigorously test the requirement of RIP1 in our 
CD95L/IAP antagonist–induced death, we tested RIP1 knock-
out MEFs. Consistent with our experiments in human cells, we 
found that RIP1 knockout cells were not sensitized to DL- 
mediated cell death in the absence of cIAPs (Fig. 4 A). How-
ever, the sensitivity of RIP1 knockout MEFs to CD95L was in-
creased when compared with wild-type cells, which is indicative 
of a more complex role of RIP1. Our results imply that RIP1 is a 
required component of a cryptic caspase-independent cell death 
that is revealed when IAPs are antagonized. However, RIP1 also 
blocks a cell death pathway in the presence of cIAPs. This dual 
role is evident in TNF-R1 signaling where in the presence of 
cycloheximide, RIP1 is protective, but in the presence of the IAP 
antagonist, RIP1 is required for cell death (Kelliher et al., 1998; 
Kreuz et al., 2004; Gaither et al., 2007; Petersen et al., 2007). To 
determine whether the kinase activity of RIP1 was required for 
this death, we treated cells with the RIP1K inhibitor Necrostatin-1 
(Fig. 4 B). When added to DL- and IAP antagonist–treated cells, 
Necrostatin-1 was unable to protect cells (Fig. 4 B). However, 
coaddition of Necrostatin-1 and zVAD-fmk resulted in complete 
protection from cell death (Fig. 4 B), annexin/propidium iodide 
(PI) positivity (Fig. S4 A), or clonogenic survival of DKO MEFs 
(Fig. 4 C). It has been suggested that the release of HMGB-1 (high 
mobility group Box-1 protein) in the cellular supernatant repre-
sents a characteristic of necrotic cell death (Scaffidi et al., 2002). 
When we investigated HMBG-1 release in IAP antagonist–treated 
cells, zVAD-fmk failed to block HMGB-1 release (Fig. S4 B). 
These data indicate that DLs activate a cell death pathway that 
results in activated caspases that are, in most situations, sufficient 
to kill cells. However, in the absence of cIAPs, a latent RIP1K-
dependent pathway is revealed. To fully block cell death, inhibi-
tion of both caspases and RIP1K is necessary.
stained with PI, and analyzed by flow cytometry. The mean + SEM is shown throughout. (B) DKO 1.5 MEFs, infected with inducible mouse cIAP1 and Flag-
cIAP2, were induced for 24 h with 4-HT. cIAP1 or Flag-cIAP2 expression was analyzed by Western blotting. -Actin served as a loading control. (C) DKO 
2.7 and DKO 3.1 MEFs were infected with inducible mouse XIAP and induced with the indicated concentrations of 4-HT for 24 h. Induction of XIAP was 
verified by Western blot analysis. Cells were treated with 20 ng/ml CD95L for 24 h in the presence or absence of 500 nM of the IAP antagonist, stained 
with PI, and analyzed by FACS. The mean + SEM of a total of six independent experiments is shown. (D) HaCaT cells were transduced with control vector 
or shRNA against cIAP1 or -2 or both. Western blot analysis shows expression of cIAP1 and -2. -Actin served as a loading control. Subsequently, cells 
were analyzed for sensitivity to 2.5 U/ml CD95L in the presence or absence of 100 nM of the IAP antagonist 24 h later by crystal violet assay. (E) HaCaT 
cells were transduced with lentiviral control vector or inducible cIAP2 as previously described (Diessenbacher et al., 2008). Cells were induced with 4-HT as 
indicated and then treated with 2.5 U/ml CD95L for 24 h in the presence or absence of 100 nM of the IAP antagonist. Viability was examined by crystal 
violet assay 24 h later. (D and E) Mean + SEM of three independent experiments is shown. MM, molecular mass.
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Figure 3. DR-mediated cell death in the presence of the IAP antagonist uses caspases and caspase-independent signaling pathways. (A) HaCaT cells were 
pre- or co-stimulated with 10 µM zVAD-fmk for 1 h and 100 nM of the IAP antagonist for 30 min. Subsequently, cells were stimulated with the indicated 
concentration of TRAIL or CD95L. The viability of cells was analyzed by crystal violet assay 18–24 h later as indicated in Materials and methods. Mean + 
SEM for three (TRAIL) or six (CD95L) independent experiments is shown. (B) HaCaT cells were either pretreated with 10 µM zVAD-fmk for 1 h or 100 nM 
of the IAP antagonist for 30 min. Cells were subsequently stimulated with 5 U/ml CD95L for 4 or 24 h. 5 µg/ml Hoechst 33342 and 5 pM SYTOX green 
were added for 15 min at 37°C, immediately followed by transmission (left) or fluorescence (right) microscopy. One of two independent experiments is 
representatively shown. (C) Stable knockdown of RIP1 in HaCaT cells was performed as indicated in Materials and methods and controlled by Western 
blot analysis for RIP1. Reprobing of the membrane with -tubulin antibodies served as a control for protein loading. MM, molecular mass. (D) Transduced 
HaCaT cells as shown in C were prestimulated for 30 min with 100 nM of the IAP antagonist or diluent alone and subsequently stimulated with the indicated 
concentrations of TRAIL or CD95L for 18–24 h followed by crystal violet assay. Mean ± SEM of three (TRAIL) or four (CD95L) independent experiments is 
shown. (E) Transduced HaCaT cells, as described in C, were preincubated with 100 nM of the IAP antagonist (Ant) for 30 min and then stimulated with 
0.5 U/ml CD95L. After 24 h, colony formation was assayed as indicated in Materials and methods. One of four representative independent experiments 
is shown. Bar, 10 µm.
Collectively, our results demonstrate that the IAP antagonist 
leads to a consistent increase in recruitment of RIP1 to the 
DISC and does not merely delay or block the transition of 
RIP1 to complex II.
Cells resistant to the sensitizing effect of the IAP antago-
nist contained cIAP2 within both the DISC and complex II de-
spite treatment with IAP antagonist, opening up the possibility 
that increased levels of cIAP2 in A5RT3 could account for the 
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Figure 4. RIP1 is an important regulator of DL-mediated cell death in the absence of cIAPs. (A) RIP1 knockout (KO) or wild type (WT) MEFs were stimulated 
with 10 ng/ml CD95L or 10 ng/ml CD95L and 500 nM of the IAP antagonist for 24 h and then assayed for cell viability using PI and flow cytometry. The 
mean + SEM of a minimum of three independent experiments is shown. (B) The combination of caspase inhibitor zVAD-fmk and RIP1K inhibitor Necrostatin-1 
completely protects HaCaT cells from DL-mediated cell death in the presence of the IAP antagonist. HaCaT cells were separately prestimulated with 10 µM 
zVAD-fmk for 1 h, 50 µM Necrostatin-1 for 1 h, and 100 nM of the IAP antagonist for 30 min, followed by stimulation with 50 ng/ml TRAIL or 2.5 U/ml 
CD95L for 18–24 h and subsequent crystal violet assay. Mean + SEM of three (TRAIL) or six (CD95L) independent experiments is shown. (C) Transformed 
cIAP1 and -2 DKO 2.3 and 2.7 MEFs were treated with 10 ng/ml CD95L for 24 h in the presence or absence of 10 µM QVD and/or 50 µM Necrostatin-1 
(Necro). Respective control wild-type MEFs were treated as the DKO MEFs but in the presence or absence of the IAP antagonist (Ant). Subsequently, cells 
were harvested, and an aliquot was replated in 6-well plates and cultured for another 4 d followed by crystal violet staining of colonies.
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Figure 5. Induction of ligand-induced receptor-bound CD95 complex (DISC) or intracellular caspase-8–containing complex (complex II) in the presence or 
absence of the IAP antagonist. (A) The CD95 DISC was precipitated from MET1 or A5RT3 cells preincubated with 10 µM zVAD-fmk and 100 nM of the IAP 
antagonist for 1 h and subsequently treated with CD95L-Fc for 2 h. CD95L DISC (left) was precipitated as detailed in Materials and methods. Precipitation of 
receptor complexes after lysis () served as internal specificity control when compared with ligand affinity precipitates (IP; +). Equal amounts of DISC (CD95L IP) 
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resistance of these cells to CD95L/IAP antagonist–induced 
death. However, when we performed knockdown of cIAP2, 
A5RT3 cells were not sensitized to CD95L-induced cell death 
by the IAP antagonist (Fig. S2 C). Moreover, overexpression of 
TRAF2 (Fig. S2 B), which is expressed at substantially lower 
levels in A5RT3 cells than in MET1 cells (Fig. S2 A), did not 
render A5RT3 cells capable of being sensitized by the IAP 
antagonist, largely excluding TRAF2 as a critical candidate 
explaining the difference between IAP antagonist–sensitive 
and –resistant cells.
cFLIP isoforms differentially contribute to 
resistance to DL-mediated cell death in the 
absence of IAPs
There are several conflicting results with respect to signaling 
capabilities of different cFLIP isoforms (for review see Yu and 
Shi, 2008). Although cFLIP recruitment appeared very similar 
in the three human cell lines tested, we wished to test whether 
cFLIP isoforms could confer resistance to IAP antagonist–
mediated sensitization to DLs. Knockdown of both expressed 
isoforms of cFLIP sensitized A5RT3 to IAP antagonist–DL 
cell death (Fig. S3). Therefore, we generated HaCaT (Fig. 6 C) 
and MET1 (Fig. S5 A) cell lines expressing different cFLIP 
isoforms. We observed that sensitivity to the IAP antagonist 
alone was increased in cells overexpressing cFLIPS but not 
cFLIPL (Fig. 6, A and B; and Fig. S5, B and C). Furthermore, 
overexpression of cFLIPS was unable to protect from DR-
mediated cell death in the presence of the IAP antagonist 
(Fig. 6 B and Fig. S5 B, panels 7 and 8) even if zVAD-fmk 
was added and despite the fact that it was perfectly competent 
at protecting cells from CD95L treatment alone (Fig. 6 B and 
Fig. S5 B, panels 2 and 3). Intriguingly, Necrostatin-1 pre-
vented cell death in short-term assays under those conditions 
(Fig. 6 B and Fig. S5 B, panel 9). In contrast, cFLIPL was 
very effective in blocking CD95L/IAP antagonist–induced 
cell death (Fig. 6, A and D; and Fig. S5 C). These experiments 
show that cFLIPS and cFLIPL differentially regulate cell death 
pathways in the absence of cIAPs in a previously unsus-
pected manner.
cFLIP isoforms differentially influence 
CD95-induced recruitment of RIP1 to  
the DISC and complex II
To elucidate the molecular mechanism of this cFLIP isoform 
phenomenon, we precipitated the CD95 DISC and com-
plex II in cells expressing cFLIPL or cFLIPS. This experi-
ment was performed in the absence of zVAD-fmk to allow 
detection of differences in caspase activity. We observed 
a dramatic increase in RIP1 levels in the DISC of control 
cells treated with the IAP antagonist despite the fact that the 
majority of RIP1 was now cleaved within the DISC (Fig. 7 A, 
lanes 1–4). Consistent with previous studies for the TRAIL 
DISC (Harper et al., 2001; Wachter et al., 2004), cFLIPL  
repressed the recruitment of RIP1 to the CD95 DISC, and 
caspase-8 and cFLIP were recruited and cleaved as previously 
published (Krueger et al., 2001; Geserick et al., 2008). In com-
plex II, an increased amount of RIP1, FADD, and cFLIPL (pro 
form as well as p43) was detected in control cells (Fig. 7 A, 
lanes 18–21). In contrast, cFLIPL and, to a substantially lesser 
extent, cFLIPS blocked the formation of complex II (Fig. 7 A, 
lanes 22–29). Interestingly, complex II formation in cFLIPS-
expressing cells was detected at low levels in the absence of 
DL stimulation (Fig. 7 A, lane 27). Inhibition of RIP1K activ-
ity with Necrostatin-1 blocked RIP1–caspase-8 interaction in 
complex II, suggesting that RIP1K activity may facilitate tran-
sition from the DISC to complex II, which is important for cas-
pase-independent cell death (Fig. 7 A, lanes 13–16 and 30–33). 
To analyze this particular aspect also in parental HaCaT cells, 
we tested DISC and complex II formation in the presence of 
zVAD-fmk, the IAP antagonist, Necrostatin-1, and the combi-
nation thereof (Fig. 7 B). Because of the known stabilization of 
the DISC and complex II by zVAD-fmk, comparisons should 
be made between similarly treated samples. Comparable levels 
of RIP1 were retained in the DISC in the presence or absence 
of Necrostatin-1 (Fig. 7 B, compare lane 12 with lane 16 for 
the CD95 IP, RIP1 vs. FADD). Comparison of lane 8 with lane 
14 for the CD95 DISC and lane 25 with lane 31 for complex 
II indicates that Necrostatin-1 did not detectably change RIP1 
association with the CD95 DISC, if the DISC-associated cleav-
age of RIP1 is taken into account (Fig. 7 B). In contrast, the 
level of RIP1 in complex II was decreased by Necrostatin-1 
(Fig. 7 B, compare lane 29 with 33, low exposure RIP1). Thus, 
RIP1K activity contributes to the translocation of a complex 
II in the parental HaCaT cells, which is in line with our over-
expression data. Thus, cIAPs normally limit RIP1 recruitment 
to the DISC and maturation of a RIP1-containing DISC into a 
RIP1-containing complex II. In the absence of cIAPs, over-
expressed cFLIPL is able to block this increased recruitment and 
prevent cell death, whereas overexpressed cFLIPS is not. Thus, 
cFLIPS is unable to block increased RIP1 recruitment even 
though it is able to completely block caspase-8 activation and 
caspase activity in the DISC. However, cFLIPS is nevertheless 
insufficient to block CD95-induced cell death.
TWEAK sensitizes to CD95L-induced cell 
death comparable with the IAP antagonist 
in cells lacking XIAP
To further understand the physiological role of cIAPs for 
CD95-induced cell death, we studied the treatment of cells 
with TWEAK, which was recently shown to induce cIAP 
or complex II (caspase-8 IP) were subsequently analyzed by Western blotting for the indicated molecules. Equal amounts of total cellular lysates (TL) were 
loaded on the same gels to allow comparison of signal strength between CD95L-IP, complex II, and total cellular lysates. (B) Kinetics of DISC (left) or complex 
II (right) in the presence or absence of the IAP antagonist. The CD95 DISC was precipitated from parental HaCaT cells either prestimulated with 100 nM 
of the IAP antagonist and 10 µM zVAD-fmk for 1 h alone or the combination of both and subsequently stimulated with 250 U/ml CD95L for the indicated 
times. CD95L DISC (left) or complex II (right) was precipitated as detailed in Materials and methods and specified for A. MM, molecular mass.
 
 o
n
 August 15, 2010
jcb.rupress.org
D
ow
nloaded from
 
Published December 28, 2009
JCB • VOLUME 187 • NUMBER 7 • 2009 1046
in keratinocytes (Leverkus et al., 2003b), which is similar 
to the role of XIAP in type II cells (Jost et al., 2009). 
TWEAK-induced sensitization similarly uncovered a caspase-
independent, RIP1-dependent form of cell death (Fig. 8 C). 
Most interestingly, TWEAK-induced sensitization was blocked 
by cFLIPL but not cFLIPS (Fig. 8 D), indicating that the find-
ings for the IAP antagonist depicted in Figs. 6 and 7 and 
Fig. S5 are also relevant in a physiological setting. Of par-
ticular interest, cells expressing cFLIPS were fully protected by 
Necrostatin-1 alone, indicating that TWEAK-induced degra-
dation of cIAPs may be sufficient to allow a CD95-induced 
degradation and sensitize cells to TNF-mediated cell death 
(Vince et al., 2008; Wicovsky et al., 2009). TWEAK treat-
ment of HaCaT cells caused down-regulation of cIAP1 and 
-2 similarly to the IAP antagonist (Fig. 8 B). HaCaT cells 
were sensitized to CD95 killing by TWEAK to the same 
extent as HaCaT cells treated with the IAP antagonist and 
were similarly protected by the combination of zVAD-fmk 
and Necrostatin-1 (Fig. 8 A). MET1 cells that expressed high 
levels of XIAP (Fig. S2 A) were substantially less sensitized 
when comparing TWEAK with the IAP antagonist (Fig. 8 A). 
These data confirm that XIAP can contribute to DL resistance 
Figure 6. cFLIP is an important regulator of DL-mediated cell death in the absence of cIAPs. (A and B) HaCaT cells were transduced with cFLIPL (A) or cFLIPS (B) 
or control vector. Total cellular lysates were analyzed for cFLIP and caspase-8. -Tubulin served as an internal control for protein loading. The mean + SEM 
of six independent experiments is shown. (C) Cells were prestimulated with 10 µM zVAD-fmk for 1 h, 50 µM Necrostatin-1 for 1 h, and 100 nM of the 
IAP antagonist for 30 min or diluent alone. Subsequently, cells were stimulated with 2.5 U/ml CD95L. The viability of cells was analyzed by crystal violet 
assay after 18–24 h. MM, molecular mass. (D) Transduced HaCaT cells were prestimulated with 100 nM of the IAP antagonist (Ant) for 30 min followed 
by co-stimulation with 2.5 U/ml CD95L. 24 h later, colony formation assay was performed as described in Materials and methods. One representative 
experiment of a total of three independent experiments is shown.
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sensitivity to caspase-independent cell death once cIAPs 
are inactivated in a given cell irrespective of the mode of 
their degradation.
caspase-independent signaling pathway to be unblocked. 
Moreover, these data suggest that the stoichiometry of 
cFLIPL and cFLIPS might be important to determine the 
Figure 7. cFLIPL but not cFLIPS blocks the for-
mation of complex II. (A) DISC or complex II 
formation in the presence or absence of the 
IAP antagonist. To allow for caspase activity, 
these experiments were performed without 
zVAD-fmk. HaCaT cells were stimulated with 
CD95L-Fc for 2 h. Subsequently, the CD95L 
DISC (left) was precipitated using ligand affin-
ity precipitation as detailed in Materials and 
methods. Precipitation of receptor complexes 
after lysis () served as an internal specificity 
control when compared with ligand affinity 
precipitates (IP; +). Equal amounts of DISC 
(CD95L IP) or complex II (caspase-8 IP) were 
subsequently analyzed by Western blotting for 
the indicated molecules. Equal amounts of total 
cellular lysates (TL) were loaded on the same 
gels to allow comparison of signal strength be-
tween IP and total cellular lysates. (B) DISC or 
complex II formation in parental HaCaT. Cells 
were either pre- or co-stimulated with 10 µM 
zVAD-fmk, 50 µM Necrostatin-1, and 100 nM 
of the IAP antagonist for 1 h and subsequently 
stimulated with 250 U/ml CD95L for 2 h. The 
CD95L DISC (left) or complex II (right) was pre-
cipitated as detailed in Materials and methods 
and specified for A. Equal amounts of DISC 
(CD95L IP) or caspase-8–interacting proteins 
(complex II) were subsequently analyzed by 
Western blotting for the indicated molecules. 
MM, molecular mass.
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Figure 8. TWEAK sensitizes to CD95L-induced cell death in a RIP1-dependent manner and is negatively regulated by cFLIPL but not cFLIPS. (A) HaCaT and 
MET1 cells were either prestimulated with 0.5 ng/ml TWEAK for 2 h or 100 nM of the IAP antagonist (Ant) for 30 min and then treated with 2.5 U/ml 
CD95L. In the same experiments, HaCaT cells were treated with 10 µM zVAD-fmk for 1 h, 50 µM Necrostatin-1 for 1 h, and 0.5 ng/ml TWEAK for 2 h. 
Subsequently, cells were stimulated with 2.5 U/ml CD95L. Viability was analyzed by crystal violet assay after 18–24 h. (B) TWEAK leads to rapid down-
regulation of cIAP1 and -2 expression in HaCaT. Cells were stimulated with 0.5 ng/ml TWEAK for the indicated time. Subsequently, total cellular lysates 
were analyzed for expression of cIAP1 or -2 by Western blotting. -Tubulin served as a loading control. MM, molecular mass. (C) Stable knockdown of 
RIP1 protects HaCaT cells from CD95L-induced cell death in the presence of TWEAK. Transduced HaCaT cells as shown in Fig. 3 C were prestimulated for 
2 h with 0.5 ng/ml TWEAK or diluent alone, subsequently stimulated with CD95L for 18–24 h, and assayed by crystal violet assay. The mean ± SEM of 
three independent experiments is shown. (D) cFLIPL but not cFLIPS protects HaCaT cells from CD95L-induced cell death in the presence of TWEAK. cFLIPL, 
cFLIPS, and vector-transduced control HaCaT as specified in Fig. 6 C were prestimulated with 10 µM zVAD-fmk for 1 h, 50 µM Necrostatin-1 for 1 h, and 
0.5 ng/ml TWEAK for 2 h or diluent alone. Cells were then stimulated with 2.5 U/ml CD95L, and viability of cells was analyzed by crystal violet assay 
after 18–24 h. (A and D) The mean + SEM of three independent experiments is shown.
Discussion
Our study contributes several important findings for the under-
standing of signaling pathways activated by DRs. We found that 
IAP antagonists, which sensitize cells to TRAIL-induced cell 
death as shown previously (Fulda et al., 2002), also dramati-
cally alter sensitivity of cells to CD95L. We studied these aspects 
in human SCC cells treated with a pharmacological inhibitor 
that induces degradation of IAPs within minutes and cIAP-
 deficient MEFs. Our data demonstrate that DL-induced signaling 
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several studies have shown that RIP1 is a direct target of the 
E3 ligase activity of cIAPs, this decrease in RIP1 modification is 
likely to be caused by a reduction in RIP1 ubiquitylation (Park 
et al., 2004; Bertrand et al., 2008; Varfolomeev et al., 2008). 
However, our experiments cannot distinguish whether cIAPs 
limit RIP1 recruitment into the DISC or whether they limit the 
accumulation of RIP1 within the DISC by K48 ubiquitylating 
RIP1, leading to its proteasomal degradation. Future studies 
using ubiquitin-specific antibodies will be able to address this 
issue (Newton et al., 2008). It is tempting to speculate that the in-
creased amount of RIP1 in the DISC and complex II subsequently 
leads to autoactivation of the kinase within the complex (Fig. 9), 
which is consistent with the activation mechanism of other 
kinases (for review see Eswarakumar et al., 2005). Identifying 
targets of RIP1K will undoubtedly promote greater insight into 
this caspase-independent cell death program (Hitomi et al., 2008). 
While this manuscript was under revision, RIP3, a kinase in-
volved in the apoptosis/necrosis shift in TNF-mediated cell death, 
was reported to interact with RIP1 (Cho et al., 2009; He et al., 
2009) and autophosphorylate in a RIP1K-dependent manner. In 
turn, activated RIP3 may regulate metabolic enzymes that could 
promote the necrotic phenotype (Zhang et al., 2009).
The precise physiological relevance of complex II forma-
tion after DL stimulation remains unresolved to date (Varfolomeev 
et al., 2005; Lavrik et al., 2008). We have now studied this com-
plex under conditions in which cIAPs are absent and find that 
complex II formation is increased whenever cIAPs are down-
regulated and contain high amounts of RIP1 in association with 
caspase-8. Remarkably, less RIP1 is detected in complex II in 
cells insensitive to IAP antagonists, which suggests that it is 
a shift of the stoichiometric balance of complex II–associated 
proteins that is relevant for the outcome of apoptotic/necrotic 
signaling. RIP1 is not only ubiquitylated in the DISC but is also 
cleaved by caspases. This fact raises a question concerning the 
impact of caspase activation on RIP1-dependent cell death. Our 
kinetic analysis of DISC and complex II formation showed a 
marked increase of full-length RIP1 in the CD95 DISC and 
complex II in the presence of zVAD-fmk when compared with 
control cells or in cleaved form in the absence of zVAD-fmk. A 
large body of evidence about alternative DR-induced cell death 
pathways for CD95 (Vercammen et al., 1998; Holler et al., 
2000) or TNF (Chan et al., 2003) has been generated by studies 
using chemical caspase inhibitors (e.g., zVAD-fmk). Based on 
our data, increased RIP1 recruitment to the DISC and/or com-
plex II in the absence of cIAPs may explain the increase in DR-
induced cell death in the presence of zVAD-fmk. However, 
zVAD-fmk is unable to fully block DISC-associated activity of 
caspase-8 in the DISC (Wachter et al., 2004) and does not block 
the enzymatic activity of the pro form of caspase-8 (Boatright 
et al., 2004), which makes it difficult to draw further mechanistic 
conclusions from such experiments. Thus, we attempted to clarify 
the role of caspases by investigating the impact of cFLIP isoforms 
as potent caspase-8 inhibitors that can block DL-mediated cell 
death. However, surprisingly, we showed that cFLIPS is insuffi-
cient to prevent the alternative RIP1 cell death pathway that 
proceeds independent of inhibition of caspases by zVAD- 
fmk. In contrast, cFLIPL, with its equivocal caspase inhibitory 
pathways are profoundly regulated by cIAPs. XIAP appeared to 
play only a minor role because even overexpression of XIAP in 
cIAP1- and cIAP2-deficient MEFs failed to increase resistance 
to CD95L. Furthermore, TWEAK-FN14 signaling, which leaves 
XIAP levels unaffected (Vince et al., 2008; Wicovsky et al., 
2009), duplicates the effects of the IAP antagonist. Although 
XIAP undoubtedly plays a role in regulating CD95 signaling in 
type II cells (Jost et al., 2009), CD95 signaling in type II cells 
requires amplification via the mitochondrial pathway to effec-
tively kill cells, and therefore, XIAP inhibits caspases at a late 
point in the signaling pathway. In our cells, we show that cIAPs 
regulate death signaling at the level of the DISC and complex II 
and suggest that this alters the cell death signal strength or charac-
ter such that it can no longer be effectively inhibited by XIAP.
CD95L induces apoptosis in many cell types. Our data 
show that the presence of cIAPs favors the apoptotic pathway and 
therefore, in the presence of cIAPs, CD95 killing can be blocked 
by caspase inhibitors such as zVAD-fmk, cFLIPS, and cFLIPL. 
However, in the absence of cIAPs, a cryptic alternative pathway 
is revealed. This type of death shows hallmarks of apoptosis, in-
cluding phosphatidylserine exposure and cleavage of substrates 
such as PARP by caspases. However, it also shows features of a 
necrotic type of cell death, including HMGB-1 release and other 
morphological characteristics. This CD95L/IAP antagonist–
induced death cannot be blocked by either zVAD-fmk or 
Necrostatin-1 alone. Therefore, the fact that the specific RIP1 
inhibitor Necrostatin-1 (Degterev et al., 2008) in combination 
with zVAD-fmk inhibits CD95L/IAP antagonist killing indicates 
that RIP1 plays a pivotal role in this death. Support for this concept 
comes from a previous study by Holler et al. (2000) that showed 
DISC recruitment of RIP1 in the complete absence of FADD. 
Several other studies have shown that blocking the CD95 or TNF 
apoptotic pathway, often with chemical caspase inhibitors, induces 
an alternative cell death pathway variously called programmed 
necrosis or necroptosis (Vercammen et al., 1998; Matsumura et al., 
2000), and in the absence of FADD or caspase-8, a caspase-
 independent cell death is operative (Bell et al., 2008; Ch’en et al., 
2008). In line with our findings, a recent study has identified 
extracellular pH as a possibility to switch DR-induced apoptotic 
cell death to RIP1-dependent necrotic cell death in the absence of 
pharmacological caspase inhibitors such as zVAD-fmk (Meurette 
et al., 2007). However, despite these insights, the molecular 
mechanisms that regulate each response under physiological con-
ditions are unresolved (for review see Festjens et al., 2007).
Using a combined genetic and biochemical approach, we 
demonstrate that cIAPs inhibit a caspase-independent cell death 
and thereby facilitate an apoptotic death. In the absence of cIAPs, 
a cryptic alternative death pathway is revealed. Using RIP1/ 
MEFs and a specific RIP1K inhibitor, Necrostatin-1, we show 
that this alternative death pathway is dependent on RIP1K activ-
ity. The recruitment of RIP1 to the CD95 membrane-bound com-
plex (CD95 DISC) is decreased by cIAPs, whereas caspase-8 
recruitment and processing is unaltered, thus suggesting 
a molecular mechanism for how cIAPs inhibit this RIP1K-
 dependent cell death pathway. Not only is the total amount of 
RIP1 increased in the CD95 DISC and complex II in the absence 
of cIAPs, the degree of RIP1 modification is also less. Because 
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experiments, may be of pathophysiological relevance. To 
test whether the phenotype we described is unique to HaCaT 
cells, we generated cFLIP-expressing MET1 cells that are p53 
wild type and express XIAP. Reassuringly, overexpression of 
cFLIPL or cFLIPS resulted in very similar results in respect to 
the isoform-specific effects of cFLIP, indicating a more general 
phenomenon. One intriguing observation is that cFLIPL p43 re-
covered in the DISC in HaCaT cells was only found at very low 
levels in cells expressing cFLIPS. Thus, one added hypothesis 
explaining the functional difference of both cFLIP isoforms in 
the absence of cIAPs may be that high levels of cFLIPS inhibit 
incorporation of cFLIPL into the DISC, and this may result in 
increased RIP1 in the DISC. Further experiments are required 
to test this hypothesis. With these considerations in mind, we 
believe our experiments suggest a remarkable and previously 
unsuspected specificity concerning the mechanism of death in-
hibition by cFLIP isoforms and open up interesting questions 
for future studies.
cFLIPL was reported to mediate binding to proteins such 
as TRAFs, RIP1, or others (for review see Kataoka, 2005). 
TRAF2 is a binding partner of cIAPs and RIP1, and in some 
cells, cFLIPL overexpression results in increased TRAF2 re-
cruitment to the CD95 DISC (Siegmund et al., 2007). We were 
consistently unable to specifically detect TRAF2 in the DISC or 
complex II using either CD95L-Fc– or antibody-mediated pre-
cipitation, and because TRAF2 overexpression did not alter the 
sensitivity of A5RT3 cells to IAP antagonist CD95L death in 
our cells, TRAF2 is unlikely to be the critical molecule mediat-
ing the different effects of cFLIPL and cFLIPS. In summary, our 
data point to novel and differential functions of cFLIP isoforms 
in the absence of cIAPs. Intriguingly, we detect an increased 
spontaneous complex II in IAP antagonist–treated cells as well 
capability, effectively blocks RIP1K-dependent death, and this 
inhibitory potential is associated with its ability to repress the 
efficient formation (or maintenance) of RIP1 in association with 
caspase-8 within the DISC and complex II. In particular, the 
interaction of RIP1 with caspase-8 in complex II is repressed by 
cFLIPL but not cFLIPS. These data point to a critical role of the 
caspase-like domain of cFLIPL that may allow cleavage of RIP1 
within the DISC, thereby limiting its ability to form complex II. 
Alternatively, cFLIPL might simply be better than cFLIPS at in-
hibiting RIP1 recruitment because of steric hindrance. Finally, 
it is also possible that cFLIP isoforms act independently of the 
DR complex, as previously suggested in lymphoid cell (Golks 
et al., 2006). For example, it is possible that nonubiquitylated 
forms of RIP1 bind to FADD independently of DISC formation, 
subsequently leading to DR-independent complex II formation 
and thereby facilitating necrotic cell death.
Our study using isoforms of cFLIP has the obvious limita-
tion of ectopic overexpression of both isoforms. HaCaT cells ex-
press low levels of endogenous cFLIP as compared with primary 
keratinocytes (Leverkus et al., 2000) and are therefore ideally 
suited for these experiments (Wachter et al., 2004). However, 
overexpression experiments can result in nonphysiological re-
sponses, and in the case of cFLIP, a lack of any clear consensus 
about the physiological relevance of different isoforms makes it 
challenging to interpret such experiments. Even in the case of 
vFLIP isoforms, which are highly similar to cFLIP isoforms, it 
is unknown what the intracellular protein levels of vFLIP are 
during a virus infection or how endogenous cFLIP could affect 
vFLIP effects. Of note, vFLIP of HHV8 dramatically increases its 
expression during late stages of HHV8-induced Kaposi sarcomas 
(Stürzl et al., 1999). Thus, a major shift of the ratio of cFLIPL 
to cFLIPS, such as that which occurs in our overexpression 
Figure 9. The role of cIAPs during DR-mediated 
cell death. cIAPs block recruitment to or degrada-
tion of RIP1 in the DISC. This signaling platform 
induces cell death in a caspase-dependent as 
well as -independent manner. A secondary com-
plex II, which is critical for necrotic cell death, 
also contains the initiator caspase-8 and FADD. 
In the presence of high levels of RIP1, RIP1 might 
be autoactivated and induce necrotic cell death 
or may require additional binding partners such 
as RIP3 (Cho et al., 2009; He et al., 2009; 
Zhang et al., 2009). cFLIPL but not cFLIPS is able 
to block complex II formation and the pro-
necrotic activity of RIP1 in complex II. In contrast, 
both isoforms block apoptotic cell death initiated 
by caspase-8 at the DISC. Caspase-8–mediated 
cleavage of RIP1 is one hypothetical mecha-
nism of down-regulation of RIP1 within the com-
plexes. Alternatively, RIP1 is only recruited to the 
DISC when ubiquitylated. cIAPs transfer ubiqui-
tin chains of currently debated specificity (e.g., 
Lys63, -48, or -11) to its substrate RIP1 (Park 
et al., 2004; Bertrand et al., 2008; Varfolomeev 
et al., 2008; Blankenship et al., 2009).
 o
n
 August 15, 2010
jcb.rupress.org
D
ow
nloaded from
 
Published December 28, 2009
1051cIAPs inhibit death receptor–mediated death • Geserick et al.
(Cancer Research UK, London, England, UK). Cell lines were cultured 
exactly as previously described (Boukamp et al., 1988; Proby et al., 2000; 
Mueller et al., 2001).
Inducible lentiviral reconstitution of murine or human IAPs
The generation of MEFs and lentiviral particles have previously been de-
scribed (Vince et al., 2007, 2008). In brief, MEFs were generated from 
embryos in accordance with standard procedures and were infected 
with SV40 large T antigen–expressing lentivirus. In vivo DKO cIAP1 and 
-2 MEFs were obtained from LoxP/LoxP cIAP1 and FRT/FRT cIAP2 mouse 
crossed first with Cre transgenic mouse followed by Flp transgenic mouse. 
DKO MEFs were generated at embryonic day (E) 10 instead of E15. To 
generate DKO MEFs expressing mouse cIAP1 or Flag-cIAP2 or mouse 
XIAP, 293T cells were transfected with packaging construct pCMV ðR8.2, 
VSVg, and the relevant lentiviral plasmid. DKO MEFs were infected with 
packaged lentivirus, and polyclonal MEFs were obtained after puromycin 
(2–5 µg/ml: pF 5xUAS selection) and hygromycin selection (100–500 µg/ml: 
GEV16 selection). HaCaT cells were transduced to express GFP or Flag-
tagged cIAP1 or -2 in an inducible manner (Diessenbacher et al., 2008). 
Cells were subsequently tested for expression of the respective proteins after 
24 h of induction with 10 or 100 nM 4-hydroxy-tamoxifen (4-HT).
Retroviral infection
For infection of HaCaT cells, the pCFG5-IEGZ retroviral vector containing 
cDNA inserts of cFLIPL, cFLIPS, or TRAF2 (provided by H. Wajant, Univer-
sity of Würzburg, Würzburg, Germany) was used as previously described 
(Leverkus et al., 2003a; Geserick et al., 2008). In brief, the amphotropic 
producer cell line NX was transfected with 10 µg of the retroviral vec-
tors by Ca phosphate precipitation. Cell culture supernatants containing 
viral particles were generated by incubation of producer cells with HaCaT 
medium (DME containing 10% FCS) overnight. After filtration (45-µm filter; 
Schleicher & Schuell), culture supernatant was added to HaCaT cells seeded 
in 6-well plates 24 h earlier in the presence of 1 µg/ml polybrene. After 
centrifugation for 3 h at 30°C, viral particle–containing supernatants were 
replaced by fresh medium. After 10–14-d Zeocin selection of bulk-infected 
cultures, FACS analysis for GFP expression (always >90%) and Western blot 
analysis were performed on polyclonal cells to confirm ectopic expression 
of the respective molecules. The empty retroviral vector served as control. 
Aliquots of cells were used for the experiments between passages 2 and 6 
after initial characterization for all subsequent experiments.
Stable siRNA expression
We used stable expression of siRNA against cFLIP or cIAP1 or -2 as recently 
published (Diessenbacher et al., 2008; Schmidt et al., 2009). RIP1 siRNA as 
well as a hyper random sequence not matched by any gene in the National 
Center for Biotechnology Information database (HRS; Vogler et al., 2007) 
were used. The HRS construct was provided by S. Fulda (Ulm University, Ulm, 
Germany). For generation of the constructs, cDNA 64-mer oligomers con-
taining RIP1-targeting sequence (nt start position +193) were cloned into the 
pSuper.retro retroviral vector (pRS) using HindIII and BglII restriction sites. 
The resulting vectors or control vector containing a sequence not found in the 
human genome were transfected into the amphotropic producer cell line 
exactly as outlined in the previous section. The retrovirus-containing superna-
tant was then used to infect A5RT3 and MET1 cells with HRS or cFLIP shRNA, 
respectively. HaCaT cells were infected either with HRS or RIP1 or cIAP1 or -2 
shRNA, and infected cells were selected with 1 µg/ml puromycin (Sigma-
Aldrich) for 3 d to obtain puromycin-resistant bulk-infected cultures for further 
analysis. The respective control constructs served as internal control. FACS 
analysis of GFP expression (always >90%) and Western blot analysis were 
performed on polyclonal cells to confirm ectopic expression of the respective 
molecules. Aliquots of cells were used for cytotoxicity assays and biochemical 
characterization between passage 2 and 6 after the antibiotic selection.
FACScan analysis
For surface staining of TRAIL receptors (TRAIL-R1 and -R2) and CD95, cells 
were trypsinized, and 4 × 105 cells were incubated with monoclonal anti-
bodies against TRAIL-R1 or -R2, CD95, or isotype-matched control IgG for 
60 min followed by incubation with biotinylated goat anti–mouse secondary 
antibodies (BD) and Cy5-phycoerythrin–labeled streptavidin (Invitrogen) as 
described previously (Wachter et al., 2004). For all experiments, 2 × 104 
cells were analyzed by FACScan (BD).
Western blot analysis
After stimulation as indicated, cells were washed twice with ice-cold PBS 
and lysed for 30 min on ice by the addition of lysis buffer (30 mM Tris-HCl, 
as increased DL-induced formation of complex II in cFLIPS-
 expressing cells. Because cFLIPL can block these events, it 
suggests that the caspase-like domain of cFLIPL is involved in 
negatively regulating complex II formation, but whether and 
which cFLIPL interacting proteins are required for this effect 
are unclear.
Our discoveries concerning the role of RIP1 in an alterna-
tive RIP1-dependent death emanating from the CD95 receptor 
were made initially with IAP antagonist drugs that rapidly de-
plete cIAP levels and antagonize XIAP. Although IAP antago-
nists have attracted great interest as cancer therapeutics, it could 
be questioned whether these findings have any physiological rel-
evance. TWEAK is able to promote the rapid degradation of 
cIAPs in an analogous manner to IAP antagonists (Vince et al., 
2008; Wicovsky et al., 2009). TWEAK and other ligands such as 
TRAIL, CD95L, or TNF are likely to be present in the same 
physiological scenario (Vince and Silke, 2006). Thus, stimulation 
of FN14, as shown in this manuscript, or possibly other receptors 
such as CD30 or -40 able to recruit cIAPs based on their protein 
structure (for example DR6, TRAIL-R2 or -R4, CD27, or EDAR) 
could deviate DR-mediated apoptotic to necrotic cell death with 
major physiological and pathophysiological consequences dur-
ing tumorigenesis or the inflammatory response in multicellular 
organisms (Leverkus et al., 2008; Kerstan et al., 2009).
Materials and methods
Materials
The following antibodies were used for Western blot analysis: antibodies to 
caspase-8 (C-15 [provided by P.H. Krammer, German Cancer Research 
Center, Heidelberg, Germany] and C-20 [Santa Cruz Biotechnology, Inc.]); 
cFLIP (NF-6; Enzo Life Sciences, Inc.); XIAP, FADD, and RIP1 (BD); caspase-3 
(CPP32; provided by H. Mehmet, Merck Frosst, Kirkland, Quebec, Can-
ada); PARP-1 (clone C-2-10; Enzo Life Sciences, Inc.); rat antibodies to 
cIAP1 (Silke et al., 2005) and cIAP2 (Vince et al., 2009); and -tubulin 
(clone 2.1; Sigma-Aldrich). Polyclonal antibodies to HMGB-1 were pur-
chased from Abcam, and TRAF2 (C-20) and CD95 antibodies (C-20) were 
purchased from Santa Cruz Biotechnology, Inc. -Actin antibodies were 
purchased from Sigma-Aldrich, and HRP-coupled monoclonal antibody to 
GFP was purchased from Clontech. His-Flag-TRAIL (HF-TRAIL) was produced 
as previously described (expression construct provided by H. Walczak, Im-
perial College London, London, England, UK; Diessenbacher et al., 2008). 
For expression of Fc-CD95L or Fc-TWEAK, we used constructs previously 
published (Bossen et al., 2006), which were provided by P. Schneider (Uni-
versity of Lausanne, Epalinges, Switzerland). 1 U of Fc-CD95L was deter-
mined as a 1:500 dilution of the stock Fc-CD95L supernatant, and 1 U/ml 
of Fc-CD95L supernatant was sufficient to kill 50% (LD50) of A375 mela-
noma cells, as previously described (Geserick et al., 2008). Ligand-
 mediated cell death was completely blocked by the addition of either 
soluble TRAIL-R2-Fc protein or CD95-Fc protein. HRP-conjugated goat anti–
rabbit, goat anti–rat IgG, and goat anti–mouse IgG antibodies and HRP-
conjugated goat anti–mouse IgG1, IgG2a, IgG2b, and IgG1- were 
obtained from SouthernBiotech. TRAIL-R1 (HS 101) and TRAIL-R2 (HS 201) 
monoclonal antibodies for FACScan analysis of surface receptor expression 
were used as previously described (Leverkus et al., 2003b) and are avail-
able from Enzo Life Sciences, Inc. CD95 antibodies (Apo-1 IgG1 and 
IgG3a) were provided by P.H. Krammer. Cy5-conjugated annexin V was 
purchased from BD. The IAP antagonist (compound A) was provided by 
TetraLogic Corp.
Cell culture
The generation of MEFs has previously been described (Vince et al., 2007, 
2008). RIP knockout mice were provided by M. Kelliher (University of Mas-
sachusetts Medical School, Worcester, MA). The spontaneously trans-
formed keratinocyte line HaCaT and the derived metastatic clone A5RT3 
(Mueller et al., 2001) were provided by P. Boukamp (German Cancer Re-
search Center). MET1 cells (Popp et al., 2000) were provided by I. Leigh 
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quently preincubated for 1 h with 10 µM zVAD-fmk and, as indicated, 
with 100 nM of the IAP antagonist at 37°C. Subsequently, cells were 
treated with 250 U/ml CD95L-Fc for 2 h. Receptor complex formation 
was stopped by washing the monolayer four times with ice-cold PBS. 
Cells were lysed on ice by the addition of 2 ml of lysis buffer (30 mM 
Tris-HCl, pH 7.5, at 21°C, 120 mM NaCl, 10% glycerol, 1% Triton 
X-100, and Complete protease inhibitor cocktail). After 30-min lysis 
on ice, the lysates were centrifuged two times at 20,000 g for 5 min 
and 30 min, respectively, to remove cellular debris. A minor fraction 
of these clear lysates was used to control for the input of the respective 
proteins. For the precipitation of the CD95 receptor and stimulation-
dependent recruited proteins, Apo-1 IgG3 antibodies (provided by P.H. 
Krammer) were added to the lysates prepared from nonstimulated as 
well as stimulated cells to precipitate the CD95-interacting proteins. The 
levels of receptor precipitated by either ligand affinity precipitation or 
caspase-8 immunoprecipitation was compared in all experiments by 
Western blotting for CD95, although direct comparison was obscured 
by the induction of SDS-stable high molecular mass complexes upon 
stimulation of CD95 (compare Fig. 5 with Fig. 7; Feig et al., 2007). 
Receptor complexes were precipitated from the lysates using 40 µl pro-
tein G beads (Roche) for 16–24 h on an end over end shaker (SB2 
rotator; Stuart) at 4°C. Ligand affinity precipitates were washed four 
times with lysis buffer before the protein complexes were eluted from 
dried beads by the addition of standard reducing sample buffer and 
boiling at 95°C. Subsequently, proteins were separated by SDS-PAGE 
on 4–12% NuPAGE gradient gels (Invitrogen) before the detection of 
DISC components by Western blot analysis.
Caspase-8 immunoprecipitation of complex II
After precipitation of the CD95 DISC, remaining lysates were centrifuged 
two times at 20,000 g for 5 min. Subsequently, 1 µg caspase-8 antibody 
(C-20; Santa Cruz Biotechnology, Inc.) was added to all lysates. The 
caspase-8–containing complexes were precipitated from the lysates by 
coincubation with 40 µl of protein G beads for 16–24 h on an end over 
end shaker at 4°C. Ligand affinity precipitates were washed four times with 
lysis buffer before the protein complexes were eluted from dried beads 
by the addition of standard reducing sample buffer and boiling at 95°C. 
Subsequently, proteins were separated by SDS-PAGE on 4–12% NuPAGE 
gradient gels before the detection of caspase-8–interacting proteins by 
Western blot analysis. To exclude remaining receptor-bound DISC com-
plexes, all caspase-8–interacting complexes were analyzed for the pres-
ence of CD95 (compare Fig. 5 with Fig. 7).
Online supplemental material
Fig. S1 shows that the IAP antagonist leads to down-regulation of cIAP1 
and -2 in HaCaT and SCC cell lines without changes in DR expression. 
Fig. S2 shows that the resistance of A5RT3 cells to CD95L/IAP antago-
nist treatment is independent of endogenous TRAF2 or cIAP2 expression. 
Fig. S3 shows that cFLIP regulates sensitivity to the combination of DL and 
IAP antagonist in A5RT3 cells. Fig. S4 shows that the IAP antagonist sensi-
tizes HaCaT cells to apoptotic and nonapoptotic cell death. Fig. S5 shows 
that cFLIPL but not cFLIPS blocks IAP antagonist DL-induced cell death in 
MET1 cells. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200904158/DC1.
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pH 7.5, at 21°C, 120 mM NaCl, 10% glycerol, 1% Triton X-100, and Com-
plete protease inhibitor cocktail [Roche]). Cellular debris was removed by 
centrifugation at 20,000 g for 10 min. 5 µg of total cellular proteins was 
supplemented with fourfold concentrated Laemmli buffer and boiled at 95°C. 
Proteins were separated by SDS-PAGE on 4–12% gradient gels (Invitrogen) 
and followed by transfer to nitrocellulose or polyvinylidene fluoride mem-
branes (GE Healthcare). Membranes were blocked with 5% nonfat dry milk 
and 3% BSA in PBS/Tween (1× PBS containing 0.05% Tween 20) for 1 h, 
washed with PBS/Tween, and incubated in PBS/Tween containing 3% non-
fat dry milk and primary antibodies as indicated overnight. After washing in 
PBS/Tween, blots were incubated with HRP-conjugated isotype-specific sec-
ondary antibody in PBS/Tween. After washing of the blots with PBS/Tween, 
bands were visualized with ECL detection kits (GE Healthcare).
Cytotoxicity assay
Crystal violet staining of attached, living cells was performed 18–24 h after 
stimulation with the indicated concentrations of DL in 96-well plates. Plates 
were washed two times with PBS. Subsequently, 50 µl of staining solution 
(0.5% crystal violet and 20% methanol) were added per well. After incuba-
tion for 20 min at room temperature, plates were washed four times with 
water. Plates were air dried, and 200 µl methanol was added per well and 
incubated for 30 min. The OD of the wells was subsequently measured by a 
plate reader (Victor3; PerkinElmer). The OD of control cultures was normal-
ized to 100% and compared with stimulated cells. For statistical analysis, the 
SEM was determined for three to seven independent experiments of each cell 
line and stimulatory condition.
Hypodiploidy analysis
Subdiploid DNA content was analyzed as previously described (Wachter 
et al., 2004). In brief, cells were stimulated with the indicated reagents for 
8 h. Cells were then detached, washed with cold PBS, and resuspended in 
buffer N (0.1% [wt/vol] Na citrate, 0.1% [vol/vol] Triton X-100, and 50 
µg/ml PI). Cells were kept in the dark at 4°C for 36–48 h, and then dip-
loidy was measured by FACScan analysis.
Immunofluorescence microscopy
For detection of nuclear morphology and integrity of the cell membrane, 
5 × 104 cells of the respective cells were seeded per well in a 12-well plate. 
After 24 h of incubation for adherence, cells were stimulated as indicated 
in the figure legend for 4 or 24 h. Subsequently, cells were incubated with 
5 µg/ml Hoechst 33342 (Polysciences Europe GmbH) and 5 pM SYTOX green 
(Invitrogen) for 15 min at 37°C, immediately followed by phase-contrast or 
fluorescence microscopy in DME + 10% FCS at room temperature. Images 
were taken with an epifluorescence microscope (Axiovert 40 CFL; Carl Zeiss, 
Inc.) equipped with a camera (18.0 monochrome without IR; Nikon) using 
a 20× NA 0.30 Ph 1 objective (Carl Zeiss, Inc.). All digital images were 
identically processed using the advanced SPOTSOFTWARE version 4.6 
(Diagnostic Instruments, Inc.).
Annexin V externalization
For the detection of phosphatidylserine externalization, cells were stimu-
lated as indicated in the figure legends. 4 or 24 h after incubation of cells, 
trypsinized cells were resuspended in 1× annexin V–binding buffer 
(10 mM Hepes, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2), and 2–4 × 
105 cells were subsequently stained with Cy5-conjugated annexin V ex-
actly according to the manufacturer (BD), followed by counterstaining 
(10 µg/ml PI) for 15 min in the dark at room temperature. For all experi-
ments, 2 × 104 cells were analyzed by FACScan.
Colony formation assays
For colony formation assay, 104 cells of parental as well as of retrovirally 
transduced HaCaT cells (HRS, shRNA RIP1, cFLIPL or cFLIPS, and the re-
spective control vectors) were seeded per well in a 24-well plate. After 
24 h of incubation, adhering cells were either separately prestimulated 
with 100 nM of the IAP antagonist for 30 min, 10 µM zVAD-fmk for 1 h, 
or 50 µM Necrostatin-1 for 1 h or in combination of all compounds fol-
lowed by co-stimulation with CD95L for 24 h. At that time, medium was 
removed, cells were washed two times with sterile PBS, and complete me-
dium was added. Cells were cultured for 3, 5, or 7 d, and subsequently, 
colonies of viable cells were stained by crystal violet as indicated in 
Cytotoxicity assay.
Ligand affinity precipitation of receptor complexes
For precipitation of the CD95L DISC, 5 × 106 cells were used for each 
condition. Cells were washed once with medium at 37°C and subse-
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Figure S1.  The IAP antagonist leads to down-regulation of cIAP1 and -2 in HaCaT and SCC cell lines, whereas DR expression is unchanged. (A) HaCaT, 
A5RT3, and MET1 cells were treated with 100 nM of the IAP antagonist or were co-stimulated with 10 µg/ml TNF-R2-Fc for the indicated time. Expression 
levels of cIAP1 and -2 and XIAP (in MET1 cells) were examined by Western blot analysis with specific antibodies to the respective proteins. Caspase-3 
cleavage was monitored over time in MET1 cells accordingly. -Tubulin served as an internal control. One of four representative results is shown. MM, mo-
lecular mass. Asterisks indicate nonspecific bands. (B) HaCaT and MET1 cells were stimulated with 100 nM of the IAP antagonist for 4 h or treated with dilu-
ent alone. Surface expression of CD95 and TRAIL-R1 and -R2 were examined with the respective antibodies to DRs and visualized by FACS. One of two 
independent experiments is shown. PE, phycoerythrin.
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Figure S2.  Resistance of A5RT3 cells  to CD95L/IAP antagonist  treatment  is  independent of TRAF2 or cIAP2. (A) Protein expression of FADD, cFLIP, 
caspase-8, TRAF2, RIP1, cIAP1 and -2, and XIAP was analyzed by Western blotting of 5 µg of total cellular lysates of HaCaT, A5RT3, and MET1 cells. 
-Tubulin served as an internal control for even loading. One of three representative results is shown. (B and C) A5RT3 cell were transduced with TRAF2 
cDNA containing retrovirus (B) or with cIAP2-specific shRNA containing retrovirus (C) or with the respective vector controls. Overexpression of TRAF2 
(B; inset) or expression of cIAP2 and -1 (C; inset) was analyzed by Western blotting of 5 µg of total cellular lysates of transduced A5RT3. -Tubulin (B) 
or -actin (C) served as an internal control for even loading of protein lysates. One of two representative results is shown. Transduced A5RT3, as shown 
in C, was prestimulated for 30 min with 100 nM of the IAP antagonist (Ant) and subsequently treated with the indicated concentrations of CD95L for 
18–24 h. The viability of cells was assayed by crystal violet assay. Mean and SEM of three independent experiments are shown. The inset of C also 
shows transduced A5RT3 cells that were stimulated for 30 min with 100 nM of the IAP antagonist, and expression of cIAP1 and -2 was determined by 
Western blotting. MM, molecular mass.
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Figure S3.  cFLIP regulates sensitivity to the combination of DL and IAP antagonist in A5RT3 cells. (A) A5RT3 cells were retrovirally transduced with either 
HRS shRNA or cFLIP-specific shRNA and selected for 3 d with 3 µg/ml puromycin. Knockdown efficiency of cFLIPL and cFLIPS was controlled by Western 
blot analysis. Reprobing of the membrane with antibodies to RIP1, FADD, caspase-8, and -tubulin served as an internal control for protein loading. A rep-
resentative of three independent experiments is shown. MM, molecular mass. (B) Transduced A5RT3 cells as shown in A were prestimulated for 30 min with 
100 nM of the IAP antagonist (Ant) and 10 µg/ml TNF-R2-Fc and subsequently stimulated with the indicated concentrations of TRAIL (left) or CD95L (right) 
for 18–24 h and assayed by crystal violet assay. The mean ± SEM of three independent experiments is shown. (C) Inhibition of caspase activity (10 µM 
zVAD-fmk) and RIP1K activity by 50 µM Necrostatin-1 completely protects A5RT3 cells from DL-mediated cell death in the presence of the IAP antagonist. 
Transduced A5RT3 cells were separately prestimulated with 10 µM zVAD-fmk for 1 h, 50 µM Necrostatin-1 for 1 h, and 100 nM of the IAP antagonist for 
30 min, followed by stimulation with 25 U/ml CD95L in triplicate wells. The viability of cells was analyzed by crystal violet assay. SEM of three independent 
experiments is shown.
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Figure S4.  The IAP antagonist sensitizes HaCaT cells to apoptotic and nonapoptotic cell death. (A) For the detection of phosphatidylserine externalization, 
HaCaT cells were pre- or co-stimulated with 10 µM zVAD-fmk for 1 h, 50 µM Necrostatin-1 for 1 h, and 100 nM of the IAP antagonist (Ant) for 30 min 
and subsequently treated with the indicated concentration of CD95L for 24 h. Cells were stained with annexin V–Cy5 and PI and then analyzed by FACS. 
One of two independent experiments is representatively shown. (B) For analysis of the release of HMGB-1 protein into the supernatant, HaCaT cells were 
pre- or co-stimulated with 10 µM zVAD-fmk for 1 h and 100 nM of the IAP antagonist for 30 min and subsequently stimulated with 5 U/ml CD95L for 24 h. 
Cell-free supernatants as well as total cellular lysates were analyzed for HMGB-1 protein expression. -Tubulin was used as a loading control. One of two 
representative experiments is shown. (C) HaCaT cells were cotransduced with GEV16- and cIAP1-Flag cDNA containing lentivirus and selected for 5 d with 
3 µg/ml puromycin and 150 µg/ml hygromycin. Inducible expression of cIAP1-Flag protein and IAP antagonist–mediated degradation of cIAP1 and -2 
were controlled by Western blot analysis after prestimulation with 100 nM 4-HT for 24 h or co-stimulation with 100 nM of the IAP antagonist for 1 h. 
Reprobing of the membrane with antibody to -tubulin served as an internal control for protein loading. A representative of two independent experiments is 
shown. (D) Transduced HaCaT cells as shown in C were prestimulated for 24 h with 100 nM 4-HT, co-stimulated for 1 h with 10 µM zVAD-fmk, co-stimulated 
for 30 min with 100 nM of the IAP antagonist, and subsequently stimulated with 2.5 U/ml CD95L for 18–24 h and assayed by crystal violet assay. SEM of 
three independent experiments is shown. All samples prestimulated with 4-HT for 24 h were normalized to control cells (e.g., set as 100%) in the presence 
of 4-HT because of the inhibitory effect of 4-HT on cellular growth under control conditions seen in all experiments. MM, molecular mass.
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Figure S5.  cFLIPL but not cFLIPS blocks IAP antagonist–DL-induced cell death in MET1 cells. (A) MET1 cells were retrovirally transduced with cFLIPL or cFLIPS 
or control vector. Total cellular lysates were analyzed for cFLIP and caspase-8. -Tubulin served as an internal control for protein loading. MM, molecular 
mass. (B and C) Cells were prestimulated with 10 µM zVAD-fmk for 1 h, 50 µM Necrostatin-1 for 1 h, and 100 nM of the IAP antagonist for 30 min or 
diluent alone. Subsequently, cells were stimulated with 2.5 U/ml CD95L in triplicate wells. The viability of cells was analyzed by crystal violet assay after 
18–24 h. The mean and SEM of three independent experiments are shown.
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